202 related articles for article (PubMed ID: 16334133)
1. Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin.
Koshiyama M; Kinezaki M; Uchida T; Sumitomo M
Anticancer Res; 2005; 25(6C):4499-502. PubMed ID: 16334133
[TBL] [Abstract][Full Text] [Related]
2. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
4. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitivity testing of paclitaxel versus docetaxel in human gynecological carcinomas: a comparison with carboplatin.
Koshiyama M; Kinezaki M; Uchida T; Sumitomo M
Anticancer Res; 2006; 26(5B):3655-9. PubMed ID: 17094381
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas: a comparison with cisplatin.
Koshiyama M; Fujii H; Kinezaki M; Ohgi S; Konishi M; Hidetaka N; Hayashi M; Yoshida M
Anticancer Res; 2000; 20(3A):1353-8. PubMed ID: 10928043
[TBL] [Abstract][Full Text] [Related]
7. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Yoshida M
Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183
[TBL] [Abstract][Full Text] [Related]
8. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
9. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
10. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
Shi W; Gu M; Liang L
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
[TBL] [Abstract][Full Text] [Related]
11. [Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer].
Kato T; Nishimura H; Yakushiji M; Noda K; Terashima Y; Takeuchi S; Takamizawa H; Suzuki M; Arai M; Ota M
Gan To Kagaku Ryoho; 1992 May; 19(5):695-701. PubMed ID: 1580643
[TBL] [Abstract][Full Text] [Related]
12. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
Muggia FM
Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530
[TBL] [Abstract][Full Text] [Related]
13. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
14. Studies of interaction of trichloro{eta2-cis-N,N-dimethyl-1-[6-(N',N'-dimethyl-ammoniummethyl)-cyclohex-3-ene-1-yl]-methylammonium}platinum(II) chloride with DNA: Effects on secondary and tertiary structures of DNA. Cytotoxic assays on human ovarian cancer cell lines, resistant and non-resistant to cisplatin.
Gay M; Montaña AM; Moreno V; Prieto MJ; Pérez JM; Alonso C
Bioorg Med Chem; 2006 Mar; 14(5):1565-72. PubMed ID: 16256352
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of cisplatin analogs against malignant ovarian tumor xenografts into nude mice.
Hamaguchi K; Miyahara K; Nishimura H; Tashiro M; Kishi N; Matsumura T; Yakushiji M; Kato T
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Nov; 40(11):1755-9. PubMed ID: 3069943
[TBL] [Abstract][Full Text] [Related]
16. Comparison of human tumour cell responses to cisplatin and ZD0473 with and without irradiation.
Raaphorst GP; Yang DP; Li LF; Malone S
Anticancer Res; 2004; 24(2B):613-8. PubMed ID: 15161002
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of nedaplatin, a novel platinum complex, with cyclophosphamide in murine and human tumor model.
Uchida N; Takeda Y; Kasai H; Maekawa R; Sugita K; Yoshioka T
Anticancer Res; 1998; 18(5A):3375-9. PubMed ID: 9858911
[TBL] [Abstract][Full Text] [Related]
18. [Ototoxicity of cis-diammine glycolato platinum, 254-S].
Horiuchi M; Miyake H; Ota K
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1327-32. PubMed ID: 1503488
[TBL] [Abstract][Full Text] [Related]
19. Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance.
Margiotta N; Natile G; Capitelli F; Fanizzi FP; Boccarelli A; De Rinaldis P; Giordano D; Coluccia M
J Inorg Biochem; 2006 Nov; 100(11):1849-57. PubMed ID: 16959321
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic activity of [Pt(pyr)(N-Etlm)Cl4].
Massacesi M; Matovic Z; Ponticelli G
Farmaco; 1993 Sep; 48(9):1327-30. PubMed ID: 8259989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
